Lu Ling, Li Yonghong, Luo Rong, Xu Junhui, Feng Jie, Wang Mingqiang
Department of Obstetrics and Gynecology, Wenjiang District People's Hospital of Chengdu, Chengdu, China.
Front Oncol. 2020 Apr 30;10:632. doi: 10.3389/fonc.2020.00632. eCollection 2020.
A series of studies have explored the prognostic value of programmed death-ligand 1 (PD-L1) in patients with endometrial cancer (EC); however, the results are controversial. Therefore, this meta-analysis was performed to estimate the associations between PD-L1 expression and the prognosis and clinicopathological features of EC. A comprehensive literature search of PubMed, Web of Science, and Embase was conducted up until September 06, 2019. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) for overall survival (OS) and progression-free survival (PFS) were computed using the random-effects model (REM) or fixed-effects model (FEM). Odds ratios (ORs) and 95% CIs were calculated to evaluate the relationship between PD-L1 and clinicopathological factors. A total of 9 studies with 1,615 patients were included in the meta-analysis. The combined data showed that high expression of PD-L1 was not significantly correlated with OS (HR = 1.20, 95% CI = 0.41-3.52, = 0.737) or PFS (HR = 1.12, 95% CI = 0.50-2.54, = 0.778) in EC. In addition, PD-L1 expression was significantly associated with poor differentiation (OR = 2.82, 95% CI = 1.96-4.06, < 0.001) and advanced stage (OR = 1.71, 95% CI = 1.12-2.60, = 0.013). This meta-analysis suggests that PD-L1 expression is not associated with poor prognosis in patients with EC. However, PD-L1 expression is positively correlated with poor differentiation and advanced tumor stage in EC.
一系列研究探讨了程序性死亡配体1（PD-L1）在子宫内膜癌（EC）患者中的预后价值；然而，结果存在争议。因此，进行了这项荟萃分析，以评估PD-L1表达与EC预后及临床病理特征之间的关联。截至2019年9月6日，对PubMed、Web of Science和Embase进行了全面的文献检索。使用随机效应模型（REM）或固定效应模型（FEM）计算总生存期（OS）和无进展生存期（PFS）的合并风险比（HRs）及95%置信区间（CIs）。计算优势比（ORs）及95% CIs以评估PD-L1与临床病理因素之间的关系。该荟萃分析共纳入9项研究，涉及1615例患者。合并数据显示，PD-L1高表达与EC患者的OS（HR = 1.20，95% CI = 0.41 - 3.52，P = 0.737）或PFS（HR = 1.12，95% CI = 0.50 - 2.54，P = 0.778）无显著相关性。此外，PD-L1表达与低分化（OR = 2.82，95% CI = 1.96 - 4.06，P < 0.001）和晚期（OR = 1.71，95% CI = 1.12 - 2.60，P = 0.013）显著相关。这项荟萃分析表明，PD-L1表达与EC患者的不良预后无关。然而，PD-L1表达与EC的低分化和肿瘤晚期呈正相关。
